Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. - Wikidata - wikimedia - TriplyDB

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

http://www.wikidata.org/entity/Q39652624

about

Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antiviral therapy and resistance with hepatitis B virus infection.Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations Review of hepatitis B therapeutics.Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial.The HBV drug entecavir - effects on HIV-1 replication and resistance Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method.Entecavir: a potent new antiviral drug for hepatitis B.Agents in clinical development for the treatment of chronic hepatitis B.Treatment of hepatitis B in decompensated liver cirrhosis.TarPred: a web application for predicting therapeutic and side effect targets of chemical compounds.New aspects on the natural history of chronic hepatitis B infection: implication for therapy.Presteady state kinetic investigation of the incorporation of anti-hepatitis B nucleotide analogues catalyzed by noncanonical human DNA polymerases Antivirals and antiviral strategies.Entecavir for the treatment of chronic hepatitis B.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.The laboratory diagnosis of hepatitis B virus.Personal view: the management of chronic hepatitis B infection.Targets of emerging therapies for viral hepatitis B and C.Future prospectives for the management of chronic hepatitis B.Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cell Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Efficacies of beta-L-D4A against Hepatitis B virus in 2.2.15 cells.Entecavir for the long-term treatment of chronic hepatitis B.Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.Update on entecavir in the management of severe forms of Hepatitis B.Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.Synthesis and anti-HIV study of novel acyclic guanine derivatives.Understanding the molecular basis of HBV drug resistance by molecular modeling.Inhibition of hepatitis B virus polymerase by entecavir.In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

P2860

Q27317068-5D789CA6-7FB1-4AAC-BE3E-6990C5BA64C9 Q28484005-385FA58D-2662-4935-9160-593BA0DC7C04 Q28748931-91281369-B10E-4CB7-A3AB-BC2A432F5FE2 Q33206221-C860EB52-FB59-4440-A430-7C0EE5C716EA Q33267067-34DAC148-B0A8-480A-8239-776CC1D443DB Q33787531-3D748EBC-6FF0-4DD8-80ED-9B62FF37305C Q33940140-9FADF7DF-AB39-4DFE-AABE-C20F0F556A2D Q34296410-4EB694F5-4F3B-433C-8858-8956EC923F17 Q34538293-BB1FC848-3F8D-4224-85A5-40B631219A34 Q34639926-049F1498-48DC-4340-A6D8-63911C9F1AEE Q34663350-869C83D0-EFAB-407C-ACA0-E2F986FB1FA5 Q35001215-F2C7075F-4A31-459C-B6BD-A0FBF50E057C Q35094702-655F912B-E45D-4796-966A-030CC4E974DB Q35185749-980042AC-F422-4646-8116-502A8F88BB1F Q35207784-EF7E8630-6022-46AD-8A1E-03C1D9B70501 Q35562182-B5497A50-3FDD-40F1-90AB-35B0E300C736 Q35628953-62B9EAE5-11CF-441C-AFE0-6C0A7128AAC4 Q35675387-2982CC2D-EF39-4629-9898-A34239A2FD29 Q35889586-CDDAA548-A051-45C5-85CC-B8AE50EE6710 Q35964745-08526790-F5D7-4540-AA69-869AEC43AC55 Q35987869-513760F5-4BC1-4F23-9D85-DD60515167FE Q36108952-305B07EE-1F51-4919-ADB1-313A305200C6 Q36171000-AEC3C058-3797-4FD3-A93F-8A906AEDB4DC Q36435893-F3463C85-2DE2-4848-B8F5-66A6E59EEAB0 Q36653655-A1BD2528-2650-4EF9-9B85-288E093E7A76 Q36841719-3BE2D21B-542B-4B6D-8480-EB9881A52A2B Q36843555-E627FECC-0FA7-46DE-859C-3CB4D45DBADB Q37009852-41AB6306-4697-4B06-B6FC-E999AD9B2A6F Q37124000-8C929C54-3100-4C82-A52C-81BB3F3E6457 Q37212962-9129105B-ED7F-4108-87FD-3ED60A3B1757 Q37626058-D4362018-D8D9-4D0C-B62E-2655A364F8C8 Q38071396-774514C4-9DBB-4F1B-A07A-4FF1FCD60ADD Q38096069-F7F1180A-1D68-4498-8DF9-08D714A0ED46 Q38201711-C8A57F2D-7CC7-4456-A8E6-5756B1122083 Q39649139-4FA97BEF-531B-431B-A32C-BAD488515165 Q40006328-ABBDAE09-6ABE-48CB-A787-58F1FD15DD33 Q40023105-965F8828-D815-4411-9595-F22AC68163FE Q40052006-C2F2C3C9-A4BA-413B-AEB7-EF16689F01B2 Q40176633-24B5C25F-D581-47C0-9D7C-4322E6CE6C4A Q40312810-92D21448-0185-46B8-9F59-0DED5882268C

P2860

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

http://www.wikidata.org/entity/Q39652624

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@en

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@nl

type

label

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@en

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@nl

prefLabel

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@en

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@nl

P1433

Q39652624-82EBC66B-60D5-495B-A686-893C4832111B

P1476

Q39652624-3B8250A6-BBBE-4BD6-89BB-53EE8AF0EB6D

P2093

Q39652624-04C86177-2AF6-4737-A382-E0F6E6A46ACA

Q39652624-101917B3-198B-4C3B-90FA-16F0E4DB3BBC

Q39652624-3DED8723-AE4D-449E-A27F-AF770CD62D7B

Q39652624-429E6546-4636-4FE5-AE3B-4576F2B96B28

Q39652624-6A703A60-3EF1-4386-8953-6A7B768FD78E

Q39652624-7F6C61D1-D4A4-4F91-930A-EEC92E1907F4

Q39652624-C9CF0FCF-2B5D-4380-8035-CF3F09EA4FA1

P2860

Q39652624-0641E169-78BE-4572-9326-969522C2CE8A

Q39652624-260B9CAB-C650-4965-A243-F1BA0DD69B56

Q39652624-289F77F7-375A-431D-86AE-0A0FCD44FD77

Q39652624-291C78E7-169B-4C7D-A92A-B5418ACD5D4F

Q39652624-42BA7D62-77AA-4EAF-82E0-F10136E3061F

Q39652624-44735032-D503-43B0-A645-8E2E797D7441

Q39652624-45667946-BFC9-4582-8F4C-1215202C6B3C

Q39652624-5B2BB2E3-7A18-4E8C-A93D-F17D5EE880E1

Q39652624-6D0E0ECC-0ED9-4A0E-8C4D-554409295602

Q39652624-6F980480-BEEA-45A1-8C4B-94304A7EE6FF

P304

Q39652624-D0C8FB92-987D-4B9F-A966-A91E764A6A53

P31

Q39652624-1276607B-C75B-4DB7-824B-BA713C60037F

P356

Q39652624-42249971-7561-4E74-81B7-E0C81D3BC662

P407

Q39652624-2405B3C9-6082-444D-9CF2-49F184E2D8A6

P433

Q39652624-38291C17-B735-4D6F-845F-5892F9A8E5BA

P478

Q39652624-FF68A43D-8A6A-4960-9B23-BB3612E61C5F

P577

Q39652624-963D237A-5800-49C5-8452-E1BDB50E3FE9

P698

Q39652624-49664727-7F69-41F2-8521-DC7FE8C3F4DD

P932

Q39652624-D96E96BD-DD62-458B-9C32-9BFDC68DEA66

P356

AAC.46.8.2525-2532.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efficacies of entecavir agains ...... ombinant polymerases in vitro.

@en

P2093

D Hernandez

http://www.w3.org/2001/XMLSchema#string

G Yamanaka

http://www.w3.org/2001/XMLSchema#string

R J Colonno

http://www.w3.org/2001/XMLSchema#string

R Rose

http://www.w3.org/2001/XMLSchema#string

S Levine

http://www.w3.org/2001/XMLSchema#string

S Weinheimer

http://www.w3.org/2001/XMLSchema#string

S Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

Rapid and efficient site-specific mutagenesis without phenotypic selection

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.

The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.

P304

2525-2532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.8.2525-2532.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12121928

http://www.w3.org/2001/XMLSchema#string

P932

127388

http://www.w3.org/2001/XMLSchema#string